407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors

Elaine Shum; Adil Daud; Matthew Reilley; Yana Najjar; John Thompson; Joaquina Baranda; R Donald Harvey; Rom Leidner; Anthony Shields; Ezra Cohen; Roger Cohen; Alain Mita; Shubham Pant; Mark Stein; Bartosz Chmielowski; Siwen Hu-Lieskovan; Catherine Fleener; Ying Ding; Sowmya Chollate; Hector Avina; Jolene Shorr; Raphael Clynes; Barbara Hickingbottom

doi:10.1136/jitc-2020-SITC2020.0407

Citation Tools

Regular and young investigator award abstracts

Clinical trials in progress

407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Shum E, Daud A, Reilley M, et al

407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors

Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0407

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password